Project Grant R21AI185841
Award Date
7/17/24
Completion Date
6/30/26
Dollars Obligated
$424K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Orlando, FL 32827, USA
Similar Awards
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
This Project Grant award of $721,194, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the structural and functional roles of membrane protein complexes involved in the cell division process of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are: (1) to study the FTSQ-FTSZ interaction and its role in stabilizing the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on developing novel antituberculosis (TB) drugs that can address emerging drug resistance. The $302,421 award to Progenra Inc., a biotechnology firm in Malvern, Pennsylvania, will fund research to evaluate parkin activators as potential treatments for both drug-sensitive and drug-resistant TB. The project aims to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
This $737,342 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and validation of advanced imaging technologies to improve the detection and study of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: 1) Develop new imaging technologies capable of detecting single MTB bacteria in vitro and in vivo; 2) Use...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $265,650 to HMH Hospitals Corporation (Hackensack University Medical Center) to conduct research on novel rifabutin analogs as a strategy to overcome drug-resistant tuberculosis (MDR/RR-TB). The primary goals are to: (1) establish the structure-activity relationship and mechanism of action of MDR-TB active rifabutin...
This $176,152 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at Rutgers, The State University of New Jersey to identify new drug targets for treating drug-tolerant strains of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to investigate how alterations in lipid metabolism and specific host environments, including cholesterol-containing...
This federal Project Grant award of $813,373.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research conducted by Rutgers, The State University of New Jersey to unravel the spectrum of intrabacterial amide hydrolysis and develop new classes of pyrazinoic acid prodrugs against pyrazinamide resistant Mycobacterium tuberculosis. The goal is to characterize diverse...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $817,405.00 to Colorado State University and its subrecipient, the University of Tennessee Health Science Center, to develop new drug regimens for treating tuberculosis (TB), including both drug-sensitive and multidrug-resistant strains. The key objectives are to: 1) manufacture and characterize inhalable dry...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $130,776 to Lake Forest College to characterize the role of the mycobacterial BrkB ortholog in the pathogenesis of tuberculosis (TB). The project aims to identify the biochemical function and substrates of the BrkB protein, determine its mechanism for requiring extracellular growth, and measure its role under...